aTyr Pharma, a San Diego CA-based protein therapeutics enterprise focused on rare diseases, completed a $49m equity financing.
An undisclosed global public investment fund joined existing investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Partners in the round.
The company intends to use the funds for clinical development of its first therapeutic program to treat rare autoimmune diseases and a rare disease pipeline in immune disorders.
Founded by The Scripps Research Institute Professor Paul Schimmel, an aminoacyl tRNA synthetase scientist and led by John Mendlein, Ph.D., CEO and executive chairman, aTyr Pharma plans to build a pipeline of innovative therapeutic products based on Physiocrine biology.
Physiocrines act as extracellular signaling molecules to orchestrate cellular homeostasis in response to stress. They are naturally occurring proteins derived from tRNA synthetases that play fundamental roles in the function of human physiology and the resolution of inflammation.